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Lesioned axons do not regenerate in the adult mammalian central nervous system, owing to the 
overexpression of inhibitory molecules such as myelin-derived proteins or chondroitin sulphate 
proteoglycans. In order to overcome axon inhibition, strategies based on extrinsic and intrinsic treatments 
have been developed. For myelin-associated inhibition, blockage with NEP1-40, receptor bodies or IN-1 
antibodies has been used. In addition, endogenous blockage of cell signalling mechanisms induced by 
myelin-associated proteins is a potential tool for overcoming axon inhibitory signals. We examined the 
participation of glycogen synthase kinase 3 (GSK3) and ERK1/2 in axon regeneration failure in lesioned 
cortical neurons. We also investigated whether pharmacological blockage of GSK3 and ERK1/2 
activities facilitates regeneration after myelin-directed inhibition in two models: i) cerebellar granule cells 
and ii) lesioned entorhino-hippocampal pathway in slice cultures, and whether the regenerative effects are 
mediated by Nogo Receptor 1 (NgR1). We demonstrate that, in contrast to ERK1/2 inhibition, the 
pharmacological treatment of GSK3 inhibition strongly facilitated regrowth of cerebellar granule 
neurons over myelin independently of NgR1. Lastly these regenerative effects were corroborated in the 
lesioned EHP in NgR1 -/- mutant mice. These results provide new findings for the development of new 
assays and strategies to enhance axon regeneration in injured cortical connections. 
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Damaged axons in the adult central nervous system do not regenerate after lesion, largely because of the 
presence of growth inhibitory molecules at the meningo-glial scar (Silver & Miller 2004, Rolls et al. 
2009). Most of these molecules derive from disrupted myelin sheaths and non-neuronal cells, which 
proliferate in the damaged region (see (Xie & Zheng 2008, Fitch & Silver 2008) for recent reviews). 
Myelin-associated proteins such as Nogo-A, myelin-associated glycoprotein (MAG) and oligodendrocyte 
myelin glycoprotein (OMgp), as well as chondroitin sulphate proteoglycans (CSPGs) together with 
secreted Semaphorins or Ephrins, have been identified as the main molecular barriers to axon regeneration 
(Silver & Miller 2004, Rolls et al. 2009). Myelin-associated inhibitors (MAIs) act primarily through a 
common neuronal receptor complex which comprises NgR1, P75, TROY and Lingo1 (Park et al. 2005, 
Wang et al. 2002, Shao et al. 2005, Schweigreiter et al. 2004). In addition to this receptor complex, MAG 
also inhibits axonal regeneration through binding to other receptors (Vinson et al. 2001, Vyas et al. 2002, 
Venkatesh et al. 2005, Goh et al. 2008), and the receptors mediating Amino-Nogo-A region inhibition 
comprise several integrins (Hu & Strittmatter 2008). Moreover, the participation of the epidermal growth 
factor receptor (EGFr) and mitogen-activated kinase pathways (ERK1/2) in CSPG- and MAI-mediated 
inhibition has also been reported (Koprivica et al. 2005). Lastly, a new MAIs receptor has recently been 
described (Atwal et al. 2008) as well as a new NgR1 ligand (Zhang et al. 2009) and a CSPG receptor 
(Shen et al. 2009), increasing the complexity of the scenario.  
 
CSPGs and myelin-based intracellular signalling are the most widely studied inhibitory mechanisms in the 
adult CNS. Although there is some controversy (Zhou et al. 2006), PKC activation and RhoA GTPase are 
considered convergent points in myelin- and CSPG-induced inhibition of axon regeneration (He & 
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Koprivica 2004, Sivasankaran et al. 2004, Hasegawa et al. 2004, Schweigreiter et al. 2004). Targets for 
RhoA or PKC activation by MAIs are linked to proteins which modulate polymerization/depolymerization 
of actin filaments, such as cofilin through LIM kinase activation (Hsieh et al. 2006) or microtubules, such 
as collapsing response mediator protein-2 (CRMP-2) (Mimura et al. 2006) or CRMP-4 (Alabed et al. 
2007).  
Several microtubule-associated proteins (MAPs) play relevant roles in microtubule dynamics and 
stabilization (Baas & Qiang 2005, Maccioni & Cambiazo 1995). Two of the most widely studied MAPs in 
healthy and neurodegenerative nervous systems are MAP1B (Riederer 2007, Gordon-Weeks & Fischer 
2000, Gonzalez-Billault et al. 2004) and Tau (Johnson & Stoothoff 2004, Nunez & Fischer 1997). These 
MAPs are regulated at the post-translational level by serine threonine phosphorylation through kinases 
such as Extracellular-Related Kinase (ERK1/2), Glycogen Synthase Kinase 3β (GSK3β) and Cyclin-
Dependent Kinase 5 (cdk5) (Riederer 2007, Gordon-Weeks & Fischer 2000, Gonzalez-Billault et al. 2004, 
Bhat et al. 2004, Del Rio et al. 2004, Gonzalez-Billault et al. 2005). MAIs regulation of cdk5, ERK1/2 
and GSK3 is different. Cdk5 and ERK1/2 activities are regulated by MAG expression (Dashiell et al. 
2002). However, no modification in GSK3 activity occurs in mag -/- mice (Franzen et al. 2001). At the 
same time, GSK3β activity has also been associated with CRMP-2 and CRMP-4 phosphorylation in 
neuroblastoma cells after IGF1 and TPA incubation, whereas cdk5 promotes only CRMP-2 
phosphorylation (Cole et al. 2006). In terms of regeneration, one study reported that pharmacological 
blockage of GSK3 activity with lithium chloride (LiCl) or SB-415286 induces a moderate regeneration 
of damaged corticospinal tract (CST) axons after dorsal lesion of the rat spinal cord (Dill et al. 2008). 
Nevertheless, the number of CST regenerative axons in this study was low following inhibitor treatments, 
in contrast to other studies using different methodologies. However, the putative participation of NgR1 in 
this process has not been explored. As recently described elsewhere (Worter et al. 2009), the response of 
different neurons to a particular inhibitor should be different. In the present study, we used translational 
research to assess whether GSK3 and ERK1/2 are activated by myelin and MAIs, using two different 
models: in 2D culture of cerebellar granule neurons and in 3D organotypic slices of the entorhino-
hippocampal (EH) connection, with the aim of exploring further the potential use of GSK3and ERK1/2 
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inhibition in promoting axon regeneration. Our results indicate that both ERK1/2 and GSK3 are 
differentially activated by myelin and Nogo-66 in cultured cerebellar granule neurons and in lesioned EH 
co-cultures. We also found that treatment with the maleimide derivatives SB-415286 and SB-216763 
inhibit activated GSK3β, thereby inducing axon regeneration in both culture models, in contrast to 
ERK1/2 inhibition by U0126. However, although the absence of NgR1 moderately increased neurite 
extension in CGN cultured over MAIs, EH co-cultures from NgR1 -/- did not regenerate after entorhino-
hippocampal pathway (EHP) axotomy as wild-type co-cultures. More relevantly, the observed neurite 
extension of CGNs and EHP regeneration is not mediated by NgR1 in either culture models since CGN 
cultures over myelin and lesioned EH cultures from NgR1 mutant mice regenerated after pharmacological 
blockage of GSK3.  
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Material and Methods 
 
Animals  
A total of 26 pregnant OF1 mice (Iffra Credo, Lyon, France) were used. The mating day was considered 
as embryonic day 0.5 (E0.5) and the day after birth was considered postnatal day 0 (P0). In addition, we 
used 20 pregnant NgR -/- mice (Zheng et al. 2005). Animals were used at postnatal stage P5-P7 (n = 65) 
for cerebellar granule neuron (CGN) cultures or P0-P1 (50 mice, 26 NgR1 -/- and 24 wild-type) for 
entorhino-hippocampal cultures. In addition, 10 adult Sprague-Dawley rats were used to obtain purified 
myelin. All animal procedures were performed in accordance with the guidelines established by the 
Spanish Ministry of Science and Technology and the European Community Council Directive 86/609 
EEC. 
 
Antibodies and biochemical reagents 
The following antibodies were used at a dilution of 1:1000 unless otherwise indicated. CS-56 antibody 
(diluted 1:200) was from Sigma (St. Louis, MO). GSK3β phospho-serine 9 (diluted 1:250), GSK3 
phospho-Y279/Y216 (diluted 1:500) and totalGSK3β were obtained from Upstate (Lake Placid, NY). Akt 
phospho-serine 473 and ERK phospho-threonine 202/phospho-tyrosine 204 were from Cell Signaling 
Technology (Beverly, MA). Total ERK and total Akt antibodies were from Transduction Laboratories 
(Lexington, KY) and Santa Cruz Biotechnology respectively. The monoclonal antibody against Actin 
(diluted 1:10,000) and Myelin-basic protein (MBP) were from Chemicon (Temecula, CA). Goat-raised 
anti-OMgp was from R&D Systems (Minneapolis, USA). The total Tau (Tau5) was from Biosource 
Europe, S.A. (Nivelles, Belgium) and phosphor-serine 202-205 Tau (AT8, diluted 1:250) was a gift from 
Prof. Jesús Ávila (CBM-UAM, CSIC, Madrid). Phalloidin-FITC and Hoechst (Bisbenzimide) were 
purchased from Sigma. Alexa Fluor 488 goat anti-mouse immunoglobulin G (IgG) (H+L) and Alexa Fluor 
568 goat anti-rabbit immunoglobulin G (IgG) (H+L) were from Molecular Probes (Leiden, Netherlands). 
The goat anti-mouse-HRP and rabbit anti-goat-HRP secondary antibodies used in Western blotting were 
purchased from DAKO (Glostrup, Denmark). Goat anti-rabbit-HRP was from Sigma. The ERK1/2 kinase 
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inhibitor U0126 was obtained from Promega (Madison, USA) and the GSK3β inhibitors SB-415286 and 
SB-216763 was purchased from Sigma (St. Louis, MO). In addition, a membrane-permeable isoform of 
the C3 transferase (TAT-C3) was used (CT04-A) (Cytoskeleton, Denver), and the NEP1-40 peptide was 
purchased (Alpha diagnostics, San Antonio, Texas).  
 
In vitro experiments 
CGNs from P5-P7 mouse pups (from wild-type and NgR1 -/- litters) were dissociated by combined 
trypsinization as described previously (Niederost et al. 2002). Cells were placed in 24-well tissue culture 
dishes (Nunc, Roskilde, Denmark) on coated coverslips (see below) and grown for 24 to 48 h in DMEM 
medium supplemented with N2 and B27. Two procedures were used to treat cells with MAIs or myelin: i) 
the cell surface was coated with purified myelin essentially as described elsewhere (Fournier et al. 2001); 
and ii) acute treatments with myelin or AP-Nogo66 were carried out. Phalloidin-labeled cultures were 
counterstained with bisbenzimide, mounted in FluoromountTM (Vector Labs, Burlingame, CA) and 
analyzed with a confocal microscope (TCS SPII, Leica). Neurite length in cultures was assessed following 
confocal image acquisition using ImageJ software.  
 
Determination of GSK3β and ERK1/2 activities 
GSK3β and ERK1/2 kinase activity assays were carried out as described elsewhere (Sayas et al. 1999, 
Simo et al. 2007). Cultured cell extracts were prepared after peptide treatments. Cells were collected with 
a scraper and homogenized in a buffer containing 20 mM HEPES (pH 7.4) 100 mM NaCl, 100 mM NaF, 
1 mM sodium orthovanadate and 5 mM EDTA. The soluble fraction was immunoprecipitated with 
agarose-conjugated antibodies against total GSK3β or total ERK1/2. Samples of 10 µl were incubated in a 
buffer containing 25 mM HEPES, pH 7.5, 1 mM DTT, 10 mM MgCl2 and a specific GSK3substrate 
peptide (pGSK3 peptide-2, Upstate Biotechnology Inc) at a final concentration of 0.75 mg/ml, and in the 
presence of γ32P-ATP. After 1 hour, the reaction was stopped with 1% H3PO4 and the reaction products 
were transferred to Immobilon membranes. The difference between kinase activity in the presence or 
absence of the GSK3 inhibitor LiCl (20 mM) was considered to reflect GSK3β kinase activity. For 
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ERK1/2 activity, reactions were initiated by resuspending immunoprecipitates in assay buffer (25 mM 
Tris–Cl [pH 7.4], 5 mM -glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2, and 1 
mM phenylmethylsulfonyl fluoride) containing 20 µM of unlabeled adenosine triphosphate, 5 µCi of γ32P-
ATP, and 5 µg of MBP (Sigma). Reaction mixtures were incubated at 30°C for 1 hour. 32P-GSK3 peptide-
2 and 32P-MBP loaded membranes were dried and exposed overnight to a phosphor-imager screen (Fuji). 
Radioactive levels were quantified using a Fuji BAS1000 phosphor-imager and PCBAS 2.0 software (Fuji 
Photo Film Co. Ltd., Japan).  
 
Entorhino-hippocampal slice co-cultures 
Entorhino-hippocampal slice co-cultures from wild-type and NgR1 -/- mice were prepared from P0 (day of 
birth) or P1 mouse pups as described elsewhere (del Rio et al. 2002, del Rio & Soriano 2010). Animals 
were anaesthetized by hypothermia, their brains were aseptically removed, and the hippocampus and the 
entorhinal cortex were dissected out. Using a McIIwain chopper, tissue pieces were cut into single 
horizontal sections (300-400 μm thick) containing both the entorhinal cortex and the hippocampus and 
maintained in Minimum Essential Medium (MEM) supplemented with glutamine (2 mM) for 45 min at 4o 
C (MEM dissecting salt solution). Selected slices were cultured using the membrane interface method 
(Stoppini et al. 1991). Slices were placed on 30-mm Ø sterile membranes (Millicell-CM, Millipore) and 
transferred into six-well tissue culture trays. Cultures were fed 1 ml of culture medium (50% MEM; 25% 
horse serum; 25% HBSS) containing 2 mM of glutamine and 0.044% NaHCO3 adjusted to pH 7.3. The 
membrane cultures were maintained in a humidified incubator at 36º C in 5% CO2. After 15 days in vitro 
(15 DIV), cultures were axotomized (see below).  
 
Axotomy of the EHP  in vitro, biocytin labeling, and quantification of regenerating axons 
After 15 DIV, the EHP of NgR1-/- and wild type was axotomized by cutting the co-cultures from the 
rhinal fissure to the ventricular side along the entire entorhino-hippocampal (EH) interface with a tungsten 
knife (see del Río et al., 2002, for details). Co-cultures were allowed to grow after axotomy for times 
ranging from 30 min to 15 days and were then processed for biochemical or morphological studies. 
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Parallel cultures were treated pharmacologically with the GSK3β inhibitors SB-415286 and SB-216763 
(NgR1 -/- and wild-type), NEP1-40 or C3-transferase for 10 days and the degree of EHP regeneration was 
determined by biocytin labelling (wild-type cultures). Two small crystals of biocytin (Sigma) were placed 
at the entorhinal slice. The following day, cultures were fixed with phosphate buffered 4% 
paraformaldehyde and processed (Del Rio et al. 1997). Some traced co-cultures of NgR1 -/- were 
processed for electron microscopy analysis as described (del Rio et al. 2002). For quantification, a 
calibrated eyepiece was used to count the number of biocytin-labelled fibres which crossed a 400-µm 
segment in the hippocampus located at a distance of 75-80 µm parallel to the lesion interphase of 
consecutive sections from each culture (40x oil immersion objective)(Mingorance et al. 2004, Mingorance 









Kinase activation in cultured CGNs.  
In contrast to AP-Mock-treated cultures, the CGNs cultures incubated with AP-Nogo66 showed increased 
ERK1/2 and Akt activity (Fig. 1A-C). This activation was also observed after incubation with myelin and 
after the radioactive kinase activity assay, in which ERK1/2 activity increased 2.5-fold after 30 min (Fig. 
1C), decreasing to a 2-fold increase at 1 h of incubation.  In addition a concentration dependent response 
was observed in ERK1/2 activation against myelin (Suppl. Fig 1). In contrast to ERK1/2, GSK3β activity 
decreased by 40% 30 min after myelin incubation, but increased rapidly to peak at 90 min, thereafter to 
further decrease in a radioactive kinase activity assay (Fig. 1D). These data was also corroborated by 
Western blotting using antibodies against phosphorylated residues of GSK3 (Fig. 1D). Next, we explored 
the degree of phosphorylation of Tau (a target of GSK3) in these conditions (Fig. 1D). Western blotting 
experiments showed a correlation of phospho-Tau with the time course of GSK3β activation (Fig. 1D). 
Thus, a parallel peak of Tau phosphorylation and GSK3 activitywas observed 90 min after incubation 
with myelin. 
 
Differential kinase activation in cultured CGNs after acute treatment with myelin or growing over 
myelin-coated substrates. 
We measured the activation of ERK1/2 and GSK3β in cultured CGNs after acute treatment with myelin or 
after growing over myelin-coated substrates for 24 h (Fig. 2). Phospho ERK1/2 and the GSK3β-
phosphoserine 9 levels (which indicate low activity of GSK3β) increased 30 min after acute myelin 
treatment (Fig. 2B). However, when CGNs were cultured over myelin substrates (substrate in Fig. 2B) for 
24 hours no relevant activation of ERK1/2 was seen in Western blots (Fig. 2B). In contrast, there was a 
relevant decrease in GSK3β-phosphoserine 9 level, which indicates GSK3β activation in CGNs growing 
over myelin for 24 hours (Fig. 2B). This activation was corroborated by radioactive kinase assays of 
GSK3β activity in CGNs cultured over myelin as above (Fig. 2C). These results suggest that, in contrast to 
GSK3inhibitors, ERK1/2 inhibitors are not appropriate for enhancing axon regeneration in cultured 
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CGNs over myelin. Indeed, when cultured over myelin, the neurite length of CGNs decreased (47.3%, 
Fig. 2D). GSK3β inactivation with SB-415286 (15 and 30 µM) increased neurite length by 21.3 % and  
21.6 % respectively (Fig. 2D). In addition, GSK3β inactivation with SB-216763 (3 and 10 µM) increased 
neurite length by 18.9 % and 23.8 % respectively (Fig. 2D). In contrast, treatments with U0126 (10 µM) 
to block ERK1/2 did not induce significant CGNs neurite regrowth over myelin (Fig. 3D). 
 
GSK3inhibition enhances outgrowth of CGNs neurites independently of NgR1 expression. 
Next we explored whether the positive effects of SB-415286 CGN neurite extension are dependent on 
NgR1 expression. For this, we prepared time-matched CGNs cultures from NgR1 deficient mice (Zheng et 
al. 2005). CGNs growing over PD-Lysine extended their neurites in a way similar to that observed in 
wild-type cultured neurons (45.2 ± 4 µm vs 42.3 ± 3.5 µm; mean ± sem, wild-type and knockout neurons 
respectively) (Fig. 2E). Moreover, NgR1 -/- CGNs growing over myelin showed reduced neurite length 
compared to NgR1 -/- neurons growing over PD-Lysine (27.7 %; 30,48 ± 2.95 vs 42.27 ± 3.53 
respectively) (Fig. 2E), but greater extension (35%) than wild-type CGNs growing over myelin-containing 
substrates (30,48 ± 2.95 vs 22,5 ± 3.3 respectively) (compare second bar of Fig. 3E and Fig. 3D 
histograms). However, when treated with 30 M SB-415286 neurite growth of NgR1 -/- cells reached 
neurite lengths similar to those seen growing over PD-Lysine (40,57 ± 3,47 vs 42.27 ± 3.53 respectively) 
(Fig. 2E).   
 
Gene expression profiling analysis after EHP axotomy in vitro.  
To evaluate the genes whose transcription was regulated after 1, 3 and 7 days after EHP axotomy (see 
Material and Methods for details), RNA samples were analyzed with Agilent whole genome mouse long 
oligonucleotide (44base) probe based microarrays. A total of 699 genes were regulated in this way, with a 
maximum of 407 genes regulated at 3 days after EHP axotomy, and clustering analysis showed that genes 
gather in 5 expression patterns (Suppl. Fig. 2). First, we were interested to test whether EHP axotomy 
induces relevant cell death or apoptotic pathways in axotomized EHP. However, no relevant changes in 
the expression of apoptotic or cell death markers were observed in axotomized EHP (Fig. 3A). As 
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expected, some genes which are known to be up-regulated after physical injury in neurons Clu (Wehrli et 
al. 2001), FGF-2 (Yoshimura et al. 2001) and IGF-2 (Gluckman et al. 1998) were up-regulated after 3 
days of EHP axotomy. Likewise, we checked whether MAIs were up-regulated after EHP axotomy. In 
fact, most of the proteins included in the arrays (e.g., MAG, MBP, MOG, MOBP and Plp) were strongly 
up-regulated at 3 and 7 days after EHP axotomy. In contrast, Rtn4 (Nogo-A) gene expression remained 
constant after EHP axotomy.   
 
Pattern of myelin inhibitory proteins, CSPGs and correlated kinase activity in axotomized EH 
organotypic slice co-cultures.  
To corroborate the data obtained in the microarrays study, we first determined the expression levels of 
myelin-associated proteins Nogo-A (Rtn4), OMgp and MBP after 30 min, 90 min, 3 days and 12 days 
following EHP axotomy at 15 DIV in wild-type slices, using the Western blot technique (Fig. 4A). As 
expected, OMgp and MBP protein levels increased in the lesioned EH co-culture, especially at 3 and 12 
days after lesion (DAL) (Fig. 4A). On the other hand, CS-56 levels were relevant over time in wild-type 
EH axotomized co-cultures, especially after 10 DAL (Fig. 4B) (see also (Mingorance et al. 2006)).  
 
Next, we analyzed the kinase activity in lesioned wild-type and NgR1 -/- EH co-cultures (Fig. 4C-D). 
ERK1/2 activity showed an initial increase at 30 min and 90 min after axotomy but decreased markedly at 
3 and 12 DAL in wild-type and NgR1 -/- cultures (Fig. 4C-D). Furthermore, immunohistochemical 
analysis of wild-type lesioned co-cultures showed a relevant increase in phosphorylated ERK1/2 close to 
the lesion site when compared to unlesioned cultures, which contrasts with the unchanged pale labeling 
observed in projecting EH neurons in control and lesioned co-cultures (Suppl. Fig. 3A-B). This increased 
phospho-ERK1/2 labeling is almost absent in the EH co-culture 2 DAL (Suppl. Fig. 3C). These results 
suggest that in EH axotomized slice co-cultures, ERK1/2 activation is mainly associated with reactive 
cells on the lesion side not affecting axotomized projecting neurons. However, we cannot rule out a 
putative participation of neuronal ERK1/2-mediated gene expression not determined in our histological 
analysis in regulating neuronal factors that could be involved in regenerative responses of damaged axons 
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or neuronal survival. In contrast, parallel Western blotting experiments demonstrated that GSK3β activity 
increased steadily after EHP lesion in wild-type slices, specially 3 and 12 DAL (Fig. 4C-D). We also 
determined that, although less relevant than wild-type slices, a GSK3activation also occurs in NgR1 -/- 
lesioned organotypic slice co-cultures at the same DAL (Fig 4C-D). Unfortunately our GSK3 antibodies 
did not recognize phosphorylated GSK3 residues in histological sections of EH co-cultures. The 
activation of GSK3 in NgR1 -/- slices suggests that other inhibitory molecules (e.g. CSPGs (Mingorance 
et al. 2006)(present results), or secreted Semaphorins (Montolio et al. 2009) also present in the lesioned 
organotypic slice may act on GSK3β activity during these late stages in both wild-type and in a lower 
level in knockout cultures likely due to the absence of the NgR1. Altogether, the present data points 
GSK3 as a putative target for enhancing axon regeneration after EHP lesion in vitro.  
 
Repair of the lesioned EHP by blocking GSK3β activity in vitro in wild-type and NgR1 -/- co-
cultures. 
To further corroborate the potential of GSK3β inhibition in EHP regeneration, we treated lesioned cultures 
from wild-type mice with SB-415286, SB-216763; and a membrane-permeable form of C3-transferase 
(TAT-C3) (Tan et al. 2007) to block RhoA-dependent activity, and with NEP1-40 peptide, as previously 
described (Mingorance et al. 2006) (Fig. 5). The ensuing cultures demonstrated that acute treatment of 
axotomized organotypic co-cultures for 10 days with SB-415286 (30 µM) resulted in the regrowth of 
numerous entorhinal axons entering the hippocampus (Fig. 5D-E,F) (25.3 ± 6.4; mean ± sem). Similarly, 
parallel axotomized organotypic co-cultures treated for 10 days with SB-216763 (10 µM) resulted in the 
regrowth of entorhinal axons (Fig. 5G) (18,5 ± 4.6; mean ± sem). In contrast, in unlesioned co-cultures 
most of the EH axons stopped at the lesion interface and very few entered into the hippocampus (Fig. 5F-
G). Regenerating axons, ending in growth cones (Fig. 5C,E), did not always grow directly towards the 
stratum lacunosum moleculare/molecular layer (slm/ml) and often grew ectopically but crossed the lesion 
(Fig. 5B-E). Compared with controls, treatment with NEP1-40 (100 µM) led to a significant increase in 
the number of regenerating biocytin-labeled axons entering the hippocampus, similar to the effect of SB-
415286 and SB-216763 (Fig. 5F). However, treatment with TAT-C3 resulted in lower regeneration (14,3 
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± 3.2) of the EHP compared to treatment with SB-415286, SB-216763 or NEP1-40 (Fig. 5F). Next, we 
prepared EH co-cultures from NgR1 -/- mice which were axotomized after 15 DIV. Due to the results 
obtained for wild-type cultures, NgR1 -/- co-cultures were treated with 30 µM of SB-415286, 10 µM of 
SB-216763 or with buffer (Fig. 5H-L). After biocytin labeling, we observed that axons did not enter the 
hippocampus in controls (Fig. 5H, K-L), in contrast to the high numbers which did so after treatment (4.1 
± 0.5 vs 18.2 ± 3.1, controls vs SB-415286 treated cultures; 3,2 ± 0.7 vs 14,6 ± 2,7, controls vs SB-216763 
treated cultures) (Fig. 5K-L). Regenerating axons displayed random trajectories in the cultures treated 
with both GSK3 inhibitors. Thus, SB-415286 treatment is most efficient than SB-216763 for improving 
axon regeneration in wild-type as well as NgR1 -/-, and reinforces the notion that the axonal regeneration 





Involvement of intracellular kinases in axon growth and regeneration. 
GSK3 plays critical roles in the regulation of neuron physiology. Highly expressed in neurons during 
development, GSK3 is crucial for establishing neuronal polarity and neurite branching and elongation 
(Garrido et al. 2007). For example, the participation of members of the Wnts (e.g., Wnt-7) and 
neurotrophins (e.g., NGF) in GSK3-mediated axon growth has been reported (e.g., (Arevalo & Chao 
2005, Zhou et al. 2008, Zhou et al. 2004)). GSK3 activity depends on the balance of tyrosine/serine 
phosphorylation. In addition, other intracellular kinases have been implicated in the neuritogenic process. 
For example, ERK1/2 activation enhances neurite outgrowth in PC12 cells (Xiao & Liu 2003), Neuro2A 
(Singleton et al. 2000) and spinal ganglion neurons (Aletsee et al. 2001) after several stimuli. Moreover, 
the activity of another kinase, PI3K, is essential for neurite elongation and maintenance, since its 
inhibition causes neurite retraction through GSK3 activation (Sanchez et al. 2001), considered a sensor 
of extracellular factors in neural growth (Luikart et al. 2008). At this respect, a recent study indicates that 
PTEN, a negative regulator or PIK3 kinase induce a robust regeneration of ganglion cells (Park et al. 
2008). This data also suggests that other PTEN-regulated pathways such as GSK3 could be involved in 
controlling axon growth (Kim & Snider 2008). It is well described that, among others, main targets of 
GSK3 activity are members of the microtubule associated proteins (e.g., Tau or MAP1B) (Cohen & 
Frame 2001), and that the microtubule cytoskeleton stability is largely impaired after lesion (Erturk et al. 
2007) .  
 
To date, few studies have analyzed the role of GSK3preventing axon regeneration. The GSK3-
mediated inhibition of axon regeneration of lesioned neurons has been studied mainly through the use of 
pharmacological treatments with LiCl. Indeed, LiCl treatment combined with ChABC (Yick et al. 2004) 
promotes axon regeneration of ganglion cells in the retina (Huang et al. 2003) and rubrospinal tract. These 
effects correlate with increased Bcl-2 expression and GSK3 inhibition (Yick et al. 2004, Dill et al. 2008). 
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Thus, a dual effect of LiCl in cell survival and axon growth is likely to be responsible for these results. 
Indeed, a single application of LiCl after spinal cord lesion does not promote the regeneration of 
rubrospinal axons (Yick et al. 2004), and the overexpression of Bcl-2 does not stimulate axon regeneration 
per se in several lesion models (Chierzi et al. 1999, Inoue et al. 2002, Sole et al. 2004, Chen & Tonegawa 
1998). In contrast, LiCl has recently been used after spinal cord lesion (Dill et al. 2008), and the results 
contrast with those reported by Alabed and co-workers (Alabed et al., 2007, Society for Neuroscience) 
with respect to the inhibition of GSK3. These differences may be attributable to direct delivery of LiCl to 
the lesion site, which would prevent cell death, or to activating infiltrating cells located at the lesion site to 
secrete growth factors or cytokines (Victoratos et al. 1997, Feinstein 1998), which may also improve axon 
regeneration (Mizusawa et al. 2003). LiCl is a non-specific GSK3 activity inhibitor (Pardo et al. 2003) 
and additional effects occur after its application. Due to these putative indirect effects we have used two 
well characterized GSK3 inhibitors instead LiCl in our experiments. 
 
Differential kinase activation after myelin treatment and experimental axotomy in vitro: lessons 
from CGNs and EH slice co-cultures and NgR1 mutants. 
Different neurons may react differently to the same inhibitory molecule (e.g., (Worter et al. 2009). Thus, it 
is reasonable to analyze the effects of MAIs inhibitory activities in different models.  
 
CGNs: We have shown that acute treatment with myelin and AP-Nogo66 activate ERK1/2 and PI3K/Akt, 
which correlates with GSK3 activity in cultured CGNs. The activation also correlates with the increased 
phosphorylation of Tau in Serine 199/202, a target of GSK3. However, ERK1/2 activation only occurs 
shortly after myelin or AP-Nogo66 exposure, which was corroborated in cultured CGNs growing over 
myelin for prolonged periods. Indeed, the application of the specific ERK1/2 inhibitor did not enhance 
axon regeneration in CGNs cultured over myelin in these conditions in contrast to GSK3 inhibitors, 
suggesting a time window of effectiveness for ERK1/2 blockage. Recent data indicates that MAIs-induced 
NgR1-mediated inhibition occurs only in acute phases following lesion (Chivatakarn et al. 2007). 
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However, this finding contrasts with other studies reporting that NgR1 inhibitors (e.g., NEP1-40 peptide) 
are useful in chronic treatment following lesion (Mingorance et al. 2006, Li & Strittmatter 2003), and raise 
the question of whether the action of NEP1-40 is NgR1-specific, which would warrant further study. Our 
present results indicate that blockage of ERK1/2 with a specific inhibitor does not enhance neurite 
outgrowth of CGNs growing over myelin after 24 h, and reinforce the notion of a transient effect of NgR1 
inhibiting neurite growth by MAIs (Chivatakarn et al. 2007).  
 
On the other hand, using NgR1 -/- CGNs growing over myelin we observed an increase in neurite length 
in mutant neurons in contrast to parallel wild-type cultures, and the length of the CGNs neurites treated 
with the GSK3 inhibitors was similar to those seen in NgR1 -/- and  NgR1 +/+ neurons growing over 
PD-Lysine. This implies the involvement of other receptors than NgR1 participating in the activation of 
GSK3 by MAIs and that ERK1/2 and GSK3β could be activated by independent intracellular pathways 
in CGNs. At this respect a participation of EGFr in ERK1/2 activation after MAIs treatment has been 
described (Koprivica et al. 2005). 
 
EH organotypic slice cultures:  In EH co-cultures, a similar model to in vivo, we described the up-
regulation of MAIs (except Nogo-A) shown using microarray and Western blotting methods. These data 
corroborated previous studies of our group (Mingorance et al. 2006, Mingorance et al. 2004, Mingorance 
et al. 2005). However, we must distinguish between early and late responses after the EHP lesion in terms 
of kinase activation. GSK3 remain active in lesioned cultures in all analyzed post-lesion days whereas 
the ERK1/2 activation is only active shortly after lesion and decreases after several days in vitro 
(especially at 3 and 12 DAL). This short ERK1/2 activation after lesion may be attributed to the activation 
of reactive glia in the lesioned area. (Suppl. Fig. 3). The participation of NgR1 in this ERK1/2 activation 
is plausible since increased NgR1 immunoreactivity in reactive astrocytes after CNS injury has been 
shown, and EGFr is involved in NgR1-mediated responses (Satoh et al. 2005, Koprivica et al. 2005).  
EGFr receptor is up-regulated in astrocytes after injury and promotes their transformation into reactive 
astrocytes. Furthermore, EGFr inhibitor PD168393 has been shown to enhance axon regeneration in the 
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injured optic nerve and promote recovery after spinal cord injury (Erschbamer et al. 2007). In these 
studies, EGFr inhibitors may reduce MAPK activation, decreasing glial reactivity and the delivery of 
inhibitory molecules impairing axon regrowth (e.g., CSPG) (Erschbamer et al. 2007). A study by Rhodes 
et al. established that the reduction in glial scar proliferation with cytosine-D-arabinofuranoside (Ara-C) 
temporarily increased the number of regenerating axons after CNS lesion, this effect decreasing after 18 
DAL (Rhodes et al. 2003). However, treatment with the selective EGFr inhibitor in the study of 
(Erschbamer et al. 2007) was only effective shortly after lesion. It would be of interest to determine 
whether this treatment is also useful in delayed application after lesion in the absence of relevant ERK1/2 
activation. On the other hand, our results indicate that although the development of the EHP connection in 
NgR1 -/- is normal (not shown), it does not spontaneously regenerate after lesion. This finding has also 
been described for the adult cortico-spinal tract in vivo (Zheng et al. 2005), although it regenerates after 
GSK3 inhibition as EH NgR1 -/- co-cultures (present data). Whilst some discrepancies exist (Dimou et 
al. 2006), mice bearing a single mutation in ligands or receptors did not show robust regeneration (Dimou 
et al. 2006), demonstrating that axon inhibition depends on different ligands/receptors and intracellular 
cascades. However, our results also indicate that GSK3 is activated in NgR1 -/- cultures and two GSK3 
inhibitors are able to enhance axon regeneration after axotomy of EHP in these slices. Total GSK3 levels 
were similar between wild-type and NgR1 -/- unlesioned organotypic slice co-cultures (not shown). 
However, although present, GSK3 activation in NgR1 -/- is lower than in wild-type axotomized co-
cultures. Thus, the characterization of the cellular factors responsible of GSK3 activation in NgR1 -/- 
cultures warrant further studies, but it is well known that secreted Semaphorins trigger the activation of 
several kinases including GSK3 (Ahmed & Eickholt 2007) (Suppl. Fig. 4). This may be of relevance in 
the delayed activation of GSK3 observed after EHP axotomy in the present study, since correlates with 
the increased expression of Semaphorins in the lesioned EHP in vitro (Montolio et al. 2009) (Suppl. Fig. 
4). Taken together, our data indicate the need to develop combined strategies for enhancing axon 
regeneration and that GSK3β inhibitory treatment can be considered as a putative target to enhance 
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Figure 1.  Activation of ERK1/2, Akt and GSK3 and phosphorylation of MAPs in cultured CGNs by 
myelin incubation.  A) Schematic procedure of the experiments. Isolation of CGNs of P5-P7 mouse pups 
for Western blotting and kinase activity assays after myelin or AP-Nogo66/Mock treatments. B) Time 
course activation of ERK1/2 and Akt in cultured CGNs after incubation with AP-Nogo66 or AP-Mock 
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containing media. The quantification of ERK1/2 and Akt-phosphorylation is shown below in the 
histograms. Values represent the mean ± sem of three separate experiments C) ERK1/2 activity in 
cultured CGNs measured by radioactive assay (see Material and Methods for details) after myelin 
treatment. The level of total ERK1/2 in autoradiographic samples is shown in the immunoblots. ** p < 
0.05 by the Student´s t test D) Histograms showing the GSK3 activity using a radioactive method 
following myelin treatment. Time course phosphorylation levels of GSK3-Ser and GSK3-Tyr after 
myelin treatment. Time course phosphorylation of Tau (-AT8) in cultured CGNs following acute myelin 
treatment. Levels of Actin and total Tau (-Tau5) are presented as loading controls. The quantification of 
the Tau phosphorylation experiments is shown in the histograms. Values represent the mean ± sem of 
three separate experiments. * p < 0.05 by the Student´s t test 
 
Figure 2.  Differential activation of ERK1/2 and GSK3 in CGNs after acute and chronic treatment 
with myelin. A) Isolation of CGNs from P5-P7 mouse pups. The CGNs were cultured over PD-Lysine or 
PD-Lysine + myelin to perform activity assays, morphological studies, kinase activity assays and also to 
carry out the pharmacological treatments. B) Immunoblot showing the activation of ERK1/2 and 
GSK3in cultured CGNs growing over PD-Lysine and treated with PBS 0.1 M or myelin (acute, left) or, 
alternatively growing over PD-Lysine or PD-Lysine + myelin (substrate, right). As observed, acute 
treatment with myelin activates ERK1/2 and increases levels of Serine 9 phosphorylated GSK3Cultured 
CGNs show no activation of ERK1/2 after 24 h in the presence of myelin. In contrast, levels of Serine 9 
phosphorylated GSK3are reduced in the same experimental conditions, indicating global activation of 
GSK3Total ERK1/2 and GSK3 are displayed as loading controls. This activation was corroborated by 
using a radioactive assay (C). Values represented in the histogram correspond to the mean ± sem of four 
separate experiments. ** p < 0.05 by the Student´s t test. D) High power microphotographs illustrating 
examples of NgR1 +/+ CGNs cultured over PD-Lysine or PD-Lysine + myelin (8 g per 35 mm ø culture 
surface). CGNs growing over PD-Lysine extend long neurites (arrows) shortly after being cultured (48 h) 
and often display several branches (asterisk). In contrast, when CGNs are cultured over PD-Lysine + 
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myelin there is a great reduction in neurite extension (arrowheads). CGNs cultured over PD-Lysine + 
myelin partially recover neurite length after treatment with SB-415286 (30 M) (arrows) in contrast to 
U0126 (10 M) treatment (arrowheads). The quantification of the experiments is shown below in the 
histogram, where values represent the mean ± sem of neurite length of 40 neurons for SB-415286 (30 
M), 42 neurons in SB-415286 (15 M) and 30 neurons for U0126 treatments in three separate 
experiments. In the lower histograms the effect of the treatment of SB-216763 on CGNs cultured over 
myelin is shown. Values represent the mean ** mean ± sem of neurite length of 40 neurons for SB-
216763 (3M) and 50 neurons for SB-216763 (10 M). p < 0.05 by the Student´s t test.  E) High power 
microphotographs illustrating examples of Phalloidin-labeled NgR1 -/- CGNs cultured over PD-Lysine or 
PD-Lysine + myelin as above. Notice that CGNs growing over PD-Lysine + myelin extend neurites 
(arrows) and often display several branches (asterisk) as in NgR1 -/- CGNs growing over PD-Lysine. 
CGNs cultured over PD-Lysine + myelin show high levels of neurite length recovery after treatment with 
GSK3 inhibitors, in contrast to NgR1 +/+ CGNs (D). The quantification of the experiments is shown 
below in the histogram, where values represent the mean ± sem of neurite length of 90 neurons for each 
experimental group in four separate experiments. ** p < 0.05 by the Student´s t test.  
 
Figure 3. Gene expression profiling analysis of apoptotic and neuronal injury genes and myelin 
associated genes after EHP axotomy in wild-type cultures. Gene expression profiling from apoptotic and 
neuronal injury markers (A) and myelin associated proteins (B) after 1, 3 and 7 days of EHP axotomy 
using mouse whole genome Agilent arrays (44k). The colour in each cell of the table represents the mean-
adjusted expression level of the gene from direct and dye-swap measurements, with blue showing 
underexpression and yellow indicating overexpression, according to the chart. Abbreviations: Casp3-9, 
Caspase 3 and 9; Bcl-2, B-cell lymphoma protein 2; Bax, BCL2-associated X protein; Bad, BCL2-
associated agonist of cell death; Mtap2, Microtubule-associated protein 2, Clu, Clusterin; FGF-2, 
Fibroblast growth factor 2; IGF-2, Insulin growth factor 2; MAG, Myelin associated glycoprotein; MBP, 
Myelin basic protein; MOG, Myelin Oligodendrocyte Glycoprotein; MOBP, myelin-associated 
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oligodendrocyte basic protein; Plp, proteolipoprotein; RTN4, Reticulon 4 (Nogo-A); MT3, 
metallothionein 3. 
 
Figure 4.  Presence of MAIs and CSPGs correlated with GSK3 and ERK1/2 kinase activation after 
EHP axotomy. A-B) Time course analysis of MAIs (A) and CSPGs (B) in axotomized EH slice co-
cultures measured by Western blotting (left). Quantification of the immunoblotting analysis is shown on 
the right. Values represent the mean ± sem of four separate experiments. * p < 0.05 by the Student´s t test. 
A relevant increase in OMgp and MBP can be seen after lesion (A). In contrast, Nogo-A remained 
constant several days after lesion compared to CS-56-positive CSPGs (B). C) Western blotting analysis of 
GSK3 and ERK1/2 kinase activity in axotomized EH slices from NgR1 +/+ (left) and NgR1 -/- (right) 
mice. As observed above, ERK1/2 decreases 3 and 12 DAL in both cases. In contrast, GSK3 activity 
increases at these stages compared to basal conditions. D) Time course of GSK3(left) and ERK1/2 
activation (right) in NgR1 +/+ and NgR1 -/- after the EHP axotomy. Notice the increasing GSK3 activity 
over time after EHP axotomy in wild-type and NgR1 -/- cultures. Values represent the mean ± sem of four 
(NgR1 +/+) and three (NgR1 -/-) separate experiments. 
 
Figure 5. Regeneration of the axotomized EHP after treatment with SB-415286 and SB-216763 in 
NgR1 +/+ and NgR1 -/- . A) Schematic diagram illustrating the in vitro axotomy model. The EHP was 
axotomized at 15 DIV (dashed line) with a tungsten needle; the cultures were treated with different drugs 
for 10 DIV and were then labeled with biocytin. B-E) Pattern of entorhino-hippocampal regeneration in 
TAT-C3 treatment (B-C) and after SB-415286 treatment (D-E). The EHP did not show a high 
regeneration level after TAT-C3 treatment in contrast to SB-415286. The presence of fibers ending in 
growth cones (arrows) in the hippocampal slice are shown in the insert boxes in C and E. F-G) 
Histograms showing the mean number of biocytin-labeled fibers which crossed a 400-m segment in the 
hippocampus located 75-80 m parallel to the transection of consecutive sections from each culture after 
TAT-C3, NEP-1-40, SB-415286 and SB-216763 treatments. The number of cultures in each treatment 
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was as follows: Control, n = 62 (41 (upper graph) + 21 (lower graph)); NEP1-40, n = 30; TAT-C3, n = 20; 
SB-415286, n = 23, SB-216763, n = 18. ** p < 0.05 by Student´s t test. H) Low power photomicrograph 
showing the absence of spontaneously entorhino-hippocampal regeneration in NgR1 -/- axotomized EHP 
(see Material and Methods for details). I-J) Pattern of entorhino-hippocampal regeneration after SB-
415286 treatment in NgR1 -/-  EH cultures. The presence of fibers ending in growth cones (arrows) in the 
hippocampal slice are shown in the insert box in I. K-L) Histograms showing the mean number of 
regenerating biocytin-labeled fibers in NgR1 -/- cultures after GSK inhibitors. The number of cultures in 
each treatment was as follows: Control, n = 43 (20 (upper graph) + 23 (lower graph)); SB-415286, n = 22. 
SB-216763, n = 16. Quantification was performed as above. ** p < 0.05 by Student´s t test. 
Abbreviations: CA1-3, hippocampal fields; DG, dentate gyrus; EC, entorhinal cortex; EHP. Entorhinal-
hippocampal pathway; S, subiculum. Scale bars: B and G = 200 m pertains to D and H; C = 100 m 
pertains to E. I =  50 m). 
 
Supplementary Figure 1. Activation of ERK1/2 after different myelin treatment. Immunoblot showing 
the activation of ERK1/2 in cultured CGNs growing over PD-Lysine and treated with PBS 0.1 M, 50 
g/ml or 100 g/ml of myelin during 30 min. Levels of Actin are presented as loading controls. 
 
Supplementary Figure 2. Gene expression regulation after EHP axotomy. A) Venn diagrams showing 
the number of overlapping regulated genes at different times following EHP axotomy. Several genes were 
regulated at more than 1 time and 9 of them were regulated at all the times studied:  Cds1, Edg2, Egr1, 
Hspa5, Insig1, Mcam, Ns5atp9, Plp, Spp1 (Complete updated gene list available on GEO database). B) 
Clustering analysis by MeV (Multiple Expression Viewer) from the regulated genes following EHP 
axotomy, showing the different expression patterns of regulated genes during the timing of the 
experiment. 
 
Supplementary Figure 3. ERK1/2 activation in EH co-cultures after axotomy. A) Low power 
photomicrograph illustrating the pattern of expression of phospho-ERK1/2 immunoreactive elements at 1 
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DAL in EH co-cultures. Notice that most immunoreactive elements are close to the lesion site. B) High  
power photomicrograph of the boxed area shown in A). Notice the presence of immunoreactive cells 
arrows. C) Photomicrograph illustrating the decrease in phospho-ERK1/2 immunoreactivity 3 DAL in 
lesioned EH co-cultures. Abbreviations as in Figure 5. Scale bars: A = 200 m and B-C 100 m.  
 
Supplementary Figure 4. Schematic diagram showing a proposed activation of GSK3by MAIs. MAIs 
acting through Nogo receptor complex activate both EGFr (1, (Koprivica et al. 2005)) leading to ERK1/2 
activation as well as Rho-kinase cascade leading to LIM kinase activation and F-Actin depolimerization 
(2, (Hsieh et al. 2006)). In addition, MAIs could activate GSK3through Nogo receptor complex trhough 
PIK3/Akt (see results) as well as other unknown receptor/s. Activated GSK3increases phosphorylated 
Tau leading to microtubule instability (3). Moreover, other inhibitory molecules could also activate 
GSK3in parallel(4), (e.g., secreted Semaphorins (Montolio et al. 2009); see Discussion). The overall F-
Actin and microtubule instability lead to a relevant neurite outgrowth inhibition in lesioned CNS neurons. 
 
Supplementary Figure 5. Electron micrograph of a regenerating EHP axon terminal (AT) in the SLM, 
which established synaptic contact (arrows) with a dendritic spine. The axon (black reaction end-product) 
was labelled by biocytin injection in the EC of the NgR1 -/- organotypic slice after 10 DIV of treatment 
with the GSK3 inhibitor SB-415286. Abreviations: AT, axon terminal. Scale bar: A = 0.5 m. 
